Approval Of First Interchangeable Biosimilar, Semglee, Is Sign Of An Improving U.S. Biosimilars Market, Despite Challenges On July 28th, the FDA approved the first interchangeable biosimilar, Semglee (long-acting insulin glargine), which implies that it can be automatically substituted at the pharmacy counter. This will usher in more competition into the insulin glargine market.